Elixia Health Enters Phase I Clinical Trials Market
Tampa-based site expands study capabilities and patient comfortHOLLYWOOD, FL / ACCESSWIRE / August 10, 2023 / Elixia Health, a leading...
Clinical Trial
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
Click here to register for webcastCompany plans to file its Earnings Report on August 14, 2023 on Form 10-Q for...
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
Trial Results Expected in Mid-2024WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical...
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised...
Ainos Celebrates First Listing Anniversary on Nasdaq
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipelineSAN DIEGO,...
Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System
FORT LAUDERDALE, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”),...
Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products
CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical...
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
CARMEL, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the...
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
Cohort 1 patients exhibited a significant immune response consistent with the mechanism of actionSafety Review Committee approved continuation to the...
GeneFab Launches to Offer Innovative Manufacturing and Synthetic Biology Design Services for a Broad Range of Genetic Medicines
– GeneFab’s cGMP facility in the San Francisco Bay Area has available capacity to support new customers with complex cell...
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapiesHINGHAM, Mass., Aug....
ABVC BioPharma Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
FREMONT, CA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical...
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in AustraliaVANCOUVER, British Columbia, Aug. 10,...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001,...
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription Drug User Fee Act (PDUFA)...
Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Patient enrollment has commenced in landmark pivotal trial for lead product...